Early safety test of new drug UCB3101 stopped short
NCT ID NCT06555601
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This study was designed to check the safety and tolerability of a single dose of UCB3101 in healthy adults aged 18 to 65. It was a first-in-human, placebo-controlled trial with 56 participants. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UP0124 1
Edegem, Belgium
Conditions
Explore the condition pages connected to this study.